Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Ravaud

Showing results (281-290 of 457) with videos related to

Pageof 46
Sort By:
BMC Medicine|January 21, 2020
The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidenceNivantha Naidoo, Van Thu Nguyen, Philippe Ravaud, et al.
International Journal of Cancer|September 21, 2017
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional studyJean-David Zeitoun, Gabriel Baron, Alexandre Vivot, et al.
Plos One|July 4, 2008
Knee arthroplasty: disabilities in comparison to the general population and to hip arthroplasty using a French national longitudinal surveyAgnes Dechartres, Isabelle Boutron, Remy Nizard, et al.
BMJ Open|December 24, 2017
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional studyJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
The American Journal of Medicine|April 25, 2015
Impact of a Doctor's Invitation on Participation in Colorectal Cancer Screening: A Cluster Randomized TrialJuliette Barthe, Elodie Perrodeau, Serge Gilberg, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 6, 2020
Behaviour of plasma citrulline after bariatric surgery in the BARIASPERM cohortFrançois Mifsud, Sébastien Czernichow, Claire Carette, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable AnalysisJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Rheumatology (Oxford, England)|October 21, 2011
Influence of vertebral fracture assessment by dual-energy X-ray absorptiometry on decision-making in osteoporosis: a structured vignette surveyChristian Roux, Gabriel Baron, Maurice Audran, et al.
BMJ (Clinical Research Ed.)|February 29, 2012
Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessorsAsbjørn Hróbjartsson, Ann Sofia Skou Thomsen, Frida Emanuelsson, et al.
Clinical and Experimental Rheumatology|June 5, 2019
Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitisAnnalisa Montante, Alicia Le Bras, Christian Pagnoux, et al.
Pageof 46

Showing results (281-290 of 457) with videos related to

Sort By:
Pageof 46
BMC Medicine|January 21, 2020
The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidenceNivantha Naidoo, Van Thu Nguyen, Philippe Ravaud, et al.
International Journal of Cancer|September 21, 2017
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional studyJean-David Zeitoun, Gabriel Baron, Alexandre Vivot, et al.
Plos One|July 4, 2008
Knee arthroplasty: disabilities in comparison to the general population and to hip arthroplasty using a French national longitudinal surveyAgnes Dechartres, Isabelle Boutron, Remy Nizard, et al.
BMJ Open|December 24, 2017
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional studyJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
The American Journal of Medicine|April 25, 2015
Impact of a Doctor's Invitation on Participation in Colorectal Cancer Screening: A Cluster Randomized TrialJuliette Barthe, Elodie Perrodeau, Serge Gilberg, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 6, 2020
Behaviour of plasma citrulline after bariatric surgery in the BARIASPERM cohortFrançois Mifsud, Sébastien Czernichow, Claire Carette, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable AnalysisJean-David Zeitoun, Joseph S Ross, Ignacio Atal, et al.
Rheumatology (Oxford, England)|October 21, 2011
Influence of vertebral fracture assessment by dual-energy X-ray absorptiometry on decision-making in osteoporosis: a structured vignette surveyChristian Roux, Gabriel Baron, Maurice Audran, et al.
BMJ (Clinical Research Ed.)|February 29, 2012
Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessorsAsbjørn Hróbjartsson, Ann Sofia Skou Thomsen, Frida Emanuelsson, et al.
Clinical and Experimental Rheumatology|June 5, 2019
Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitisAnnalisa Montante, Alicia Le Bras, Christian Pagnoux, et al.
Pageof 46